Synapse

← Mathew S. Maurer

Papers by Mathew S. Maurer

Page 1 · newest first

  1. Injurious Falls and Mortality With Intensive Blood Pressure Treatment in SPRINTThe American Journal of Medicine · 2026
  2. Effects of Eplontersen on Cardiac Structure and Function in Patients With Transthyretin Amyloidosis With Cardiomyopathy: Insights from the CARDIO-TTRansform Trial.2026
  3. Clinical characteristics, treatment, and long-term outcomes in 987 patients with splenic marginal zone lymphoma to inform treatment and surveillance strategiesBlood Cancer Journal · 2026
  4. Myocardial Responses to Eplontersen in Transthyretin Amyloid Cardiomyopathy: The CARDIO-TTRansform CMR studyCirculation · 2026
  5. Long-Term Impact of Vutrisiran in Patients With TTR Amyloidosis With Cardiomyopathy: 1-Year Efficacy and Safety Outcomes From the HELIOS-B Open-Label ExtensionCirculation · 2026
  6. Ventricular Structure and Function in Hypertensive Participants With Heart Failure and a Normal Ejection FractionJournal of the American College of Cardiology · 2007
  7. Recognizing Cardiac Amyloidosis Phenotype by Echocardiography Increases Downstream TestingJournal of the American Society of Echocardiography · 2023
  8. Transcriptomics Identifies a Small Set of Circulating Biomarkers and Signaling Pathways Dysregulated in Hypertrophic CardiomyopathyJACC Heart Failure · 2026
  9. Multiple musculoskeletal procedures over time and the risk of amyloidosis: a Danish nationwide cohort studyAmyloid · 2026
  10. Deprescribing in Older Adults With Cardiovascular DiseaseJournal of the American College of Cardiology · 2019
  11. Machine Learning of Echocardiographic Left Ventricular Myocardial Radiomics for Identification of Transthyretin Amyloid CardiomyopathyJACC Advances · 2026
  12. Response by Maurer and Fontana to Letter Regarding Article, “Coramitug, a Humanized Monoclonal Antibody for the Treatment of Transthyretin Amyloid Cardiomyopathy: A Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial”Circulation · 2026
  13. Eplontersen with and without background transthyretin stabilizers in transthyretin amyloid cardiomyopathy: secondary analysis of a phase 3, randomized controlled trialNature Medicine · 2026
  14. Emerging therapies and translational tools for drug development in systemic amyloidosis: insights from the International Society of Amyloidosis Scientific WorkshopAmyloid · 2026
  15. In Participants Treated With Acoramidis, Addition of Concomitant Tafamidis Did Not Further Increase Serum TTR LevelsJournal of the American College of Cardiology · 2025
  16. Phenotypic Considerations for Tafamidis Use in a Real-World Cohort of Older Patients with Transthyretin Amyloid CardiomyopathyCardiology and Therapy · 2026
  17. Proteomics Profiling Reveals Molecular Subtypes of Transthyretin Cardiac AmyloidosisCirculation Heart Failure · 2026
  18. Sex Differences in a Contemporary, Real-World Cohort of Patients with Transthyretin Amyloid Cardiomyopathy Treated with TafamidisCardiology and Therapy · 2026
  19. Effect of Vutrisiran According to Baseline Tafamidis Use in Transthyretin Amyloidosis With CardiomyopathyJournal of the American College of Cardiology · 2026
  20. Effect of Anselamimab on Cardiac Structure and Function in Patients With Light Chain Amyloidosis: Insights From the CARES Clinical TrialsCirculation · 2026
  21. 124 I-Evuzamitide Positron Emission Tomography/Computed Tomography for Diagnosing Cardiac AmyloidosisJAMA · 2026
  22. Long-Term Efficacy and Safety of Acoramidis in ATTR-CM: Initial Report From the Open-Label Extension of the ATTRibute-CM TrialCirculation · 2024
  23. Effect of Aficamten on Cardiac Structure and Function in Patients with Symptomatic Nonobstructive Hypertrophic CardiomyopathyCirculation · 2026
  24. Aficamten for Symptomatic Nonobstructive Hypertrophic CardiomyopathyNew England Journal of Medicine · 2026
  25. Eplontersen for Transthyretin Amyloid CardiomyopathyNew England Journal of Medicine · 2026
  26. Impact of Tafamidis on Transthyretin Concentration and Its Relation to All-Cause Mortality in Patients with Transthyretin Amyloid Cardiomyopathy: An Analysis from ATTR-ACTCardiology and Therapy · 2026
  27. Global Efficacy of Aficamten in Nonobstructive Hypertrophic Cardiomyopathy: Results From ACACIA-HCMCirculation · 2026
  28. Critical Comparison of Documents From Scientific Societies on Cardiac AmyloidosisJournal of the American College of Cardiology · 2022
  29. Guidelines for the management of hereditary ATTR amyloidosis 2026Amyloid · 2026
  30. Association of Carpal Tunnel Syndrome With Amyloidosis, Heart Failure, and Adverse Cardiovascular OutcomesJournal of the American College of Cardiology · 2019
  31. Temporal Trends in Incidence and Prevalence of Transthyretin Amyloid Cardiomyopathy in the United StatesJournal of the American Heart Association · 2026
  32. Long‐Term Outcomes of Mayo Stage IIIb AL Amyloidosis Treated With Daratumumab‐Based Frontline TherapyAmerican Journal of Hematology · 2026
  33. Diagnostic Performance of the Mayo ATTR-CM Score in Diverse PopulationsJACC Advances · 2026
  34. Nutrition Assessment and Dietary Interventions in Heart FailureJournal of the American College of Cardiology · 2022
  35. Genotype and Phenotype of Transthyretin Cardiac AmyloidosisJournal of the American College of Cardiology · 2016
  36. Frailty Assessment in the Cardiovascular Care of Older AdultsJournal of the American College of Cardiology · 2013
  37. Transthyretin Amyloid CardiomyopathyJournal of the American College of Cardiology · 2019
  38. Deep Learning Electrocardiographic Analysis for Detection of Left-Sided Valvular Heart DiseaseJournal of the American College of Cardiology · 2022
  39. ATTR-CM: What do we know about blood levels of the TTR protein? A discussion with expertsTherapeutic Advances in Cardiovascular Disease · 2026
  40. 26-a-11151-Acc Long-Term Benefits With Acoramidis on Kansas City Cardiomyopathy Questionnaire-Overall Summary (Kccq-Os) Score and Serum Transthyretin Levels in Patients With Transthyretin Amyloid Cardiomyopathy (Attr-Cm)Journal of the American College of Cardiology · 2026
  41. Changing Patterns of Diagnosis and Survival in Transthyretin Cardiac Amyloidosis: A Multicenter Cohort StudyJournal of the American Heart Association · 2025
  42. Coramitug, a Humanized Monoclonal Antibody for the Treatment of Transthyretin Amyloid Cardiomyopathy: A Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled TrialCirculation · 2025
  43. Endothelial Cell‐Related Proteins in Plasma Predict Major Adverse Cardiovascular Events and Worsening Heart Failure in Patients With Hypertrophic CardiomyopathyJournal of the American Heart Association · 2025
  44. A collaborative approach to amyloidosis and a multidisciplinary care framework – position statement from the International Society of AmyloidosisAmyloid · 2025
  45. Early Access to Tafamidis for Patients With Transthyretin Amyloid CardiomyopathyJACC Advances · 2025
  46. A cautionary case series: tafamidis mistreatment following erroneous diagnosis of transthyretin cardiac amyloidosisAmyloid · 2025
  47. Concurrent TTR and AL AmyloidosisJACC Case Reports · 2025
  48. Transthyretin Cardiac Amyloidosis in Older Black and Hispanic Individuals With Heart FailureJAMA Cardiology · 2025
  49. Pharmacotherapy of cardiovascular diseases from herbs and pills to nucleic acidsEuropean Heart Journal · 2025
  50. Prevalence and Phenotype of Transthyretin Val122Ile Variant in the Hispanic Community Health Study/Study of LatinosJACC Advances · 2025